Navigation Links
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
Date:11/16/2011

SAN DIEGO, Nov. 15, 2011 /PRNewswire/ -- Ambit Biosciences Inc. today announced the appointment of Michael A. Martino as President, Chief Executive Officer and member of the Board of Directors. Martino brings to Ambit a nearly 30-year track record in leading privately held and publicly traded life sciences companies through late-stage clinical development, fundraising, commercial and business development activities, including new product launches and mergers and acquisitions.  He replaces Alan Lewis, Ph.D., who announced his departure earlier this year and recently left the company after supporting the transition to Martino's appointment.

"We are pleased that Mike, having completed diligence sees what we see: a promising lead drug candidate, quizartinib, with compelling interim data in a high medical need population and valuable earlier-stage assets that together make up an impressive pipeline," said Faheem Hasnain, Ambit's Chairman.  "Mike is joining a talented and committed Ambit team that has successfully moved three drug candidates into the clinic, any one of which could be a lead drug in an earlier stage company, and discovered several promising preclinical compounds. Mike will provide the necessary experience and leadership to drive quizartinib through the approval process and prioritize and focus development of the pipeline."

Martino said, "I am pleased to join Ambit and continue the development of its rich pipeline of early and late-stage programs.  There is tremendous promise in quizartinib where the interim Phase 2 data suggest durable leukemic control in relapsed/refractory acute myeloid leukemia patients with FLT3-ITD mutations who otherwise have very limited treatment options available.  I also look forward to focusing and leading the development of our earlier clinical stage assets, AC430 and AC480, which are targeted at large patient populations with unmet needs."

From 1999 to 2008, Martino served as Presid
'/>"/>

SOURCE Ambit Biosciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Ambit Biosciences Announces Transition in Company Leadership
2. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
3. Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
5. Neurocrine Biosciences Reports Third Quarter 2011 Results
6. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
7. GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloittes 2011 Technology Fast 500™
8. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
9. Amarillo Biosciences Issues Corporate Update
10. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
11. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... April 1, 2015  ValGenesis Inc., the market leader ... that it has completed its Service Organization Controls 2 ... (AICPA, Professional Standards) for the period of January 1 ... ... The SOC 2 examination is ...
(Date:4/1/2015)... , Mar. 30, 2015 Research and Markets ... addition of the "Blood Screening Market by ... Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting), Product ... - Forecasts to 2019 " report to ... is expected to reach $2.55 billion by 2019 ...
(Date:4/1/2015)... NEW YORK , April 1, 2015 ... biopharmaceutical company advancing protein biologic therapies and oncology ... the Company,s 2014 achievements and a strategic update ... progress the Company has made in the areas ... its MuGard programs, the FDA clearance of the ...
(Date:4/1/2015)... The concept of “spot reducing” areas is a huge ... Fasciology, Ashley Black, says that even the idea of being ... to wait for the whole fat system to reduce is ... cooling procedures, the only well known way to spot ... a highly invasive procedure.” It is common knowledge that weight ...
Breaking Biology Technology:ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 2ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 3Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 2Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 2PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 5PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 6Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 2Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 3
... The medical imaging company SyntheticMR AB, ... order for their magnetic resonance imaging software from Umeå ... be used in clinical practice to monitor the treatment ... SyMRI Diagnostics, includes tools to automatically estimate a measure ...
... Verenium Corporation (Nasdaq: VRNM ), a leading ... of high-performance enzymes, today announced James Levine, President and ... Mr. Levine will present at the upcoming ... September 12, 2011.  The presentation is expected to begin ...
... Switzerland, September 1, 2011 Study Assessing ... in mid 2012 Kuros Biosurgery AG, a ... and bioactive-biomaterial combination products for trauma, wound and spinal ... a Phase IIb clinical trial designed to investigate KUR-211 ...
Cached Biology Technology:Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation 2Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation 3Verenium to Present at Upcoming Conferences 2Verenium to Present at Upcoming Conferences 3Kuros Completes Patient Recruitment in a Phase IIb Clinical Trial With KUR-211 for Diabetic Foot Ulcers 2Kuros Completes Patient Recruitment in a Phase IIb Clinical Trial With KUR-211 for Diabetic Foot Ulcers 3
(Date:3/20/2015)... , Mar. 20, 2015 Research and Markets ... addition of the "India Sensors Market Forecast ... The sensor market is projected to ... Consumer electronics, automotive, industrial and healthcare ... in the country. In addition, adoption of MEMS ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... wallet is one of the products featured in 2015 ... 20th at 11:00 PM EST on the DIY Network. ... Las Vegas , site of the ...
(Date:3/19/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... this week on Washington DC,s Fox ... segment "The Next Great Thing", host Laura Evans ... and ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... In 2005, the overall cost of patients' time spent on cancer ... to a new study in the January 3 issue of the ... for the 11 cancers studied and for different phases of cancer ... the direct medical costs of cancer care, but few have attempted ...
... the January issue of the journal Cell Metabolism, published by ... the formation of a poorly understood type of muscle. Moreover, ... IIX fibers were able to run farther and at higher ... ultimately lead to novel drugs designed to change the composition ...
... insect cells ?not in eggs, where flu vaccines currently available ... effective as conventional vaccines in protecting people against the flu, ... the Journal of the American Medical Association. , Removing eggs ... health officials seeking to protect the population from seasonal flu ...
Cached Biology News:Study calculates patient time costs associated with cancer care 2Study calculates patient time costs associated with cancer care 3'Marathon mice' elucidate little-known muscle type 2'Marathon mice' elucidate little-known muscle type 3Bypassing eggs, flu vaccine grown in insect cells shows promise 2Bypassing eggs, flu vaccine grown in insect cells shows promise 3
HybriWell™ hybridization sealing system, 20 mm diameter chamber, 0.15 mm deep *set of 100*...
Recombinant Equine TNF-alpha/TNFSF1A, CF...
GRADIENT MAKER, 30 ML, 1 EA. Category: Protein Vertical Instruments....
DALT GRADIENT MAKER,230V, 1 EA. Category: 2D DALT Systems....
Biology Products: